Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 16/20 | 0.50 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | IARS1 | P41252 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL673906 | 0.82 | SLC5A2 (0.62) | SLC5A2SLC5A1 | |
| SCHEMBL14949166 | 0.76 | CYP2C19 (0.56) | SLC5A2SLC5A1CYP2C19CYP2C9THRB | |
| SCHEMBL19189971 | 0.76 | CYP2C19 (0.56) | SLC5A2SLC5A1CYP2C19CYP2C9THRB | |
| SCHEMBL677558 | 0.75 | SLC5A2 (0.63) | SLC5A2SLC5A1 | |
| SCHEMBL677592 | 0.75 | SLC5A2 (0.55) | SLC5A2SLC5A1 | |
| SCHEMBL677585 | 0.74 | SLC5A2 (0.50) | SLC5A2SLC5A1 | |
| SCHEMBL677584 | 0.73 | SLC5A2 (0.60) | SLC5A2SLC5A1 | |
| SCHEMBL676796 | 0.69 | SLC5A2 (0.66) | SLC5A2SLC5A1 | |
| SCHEMBL677530 | 0.69 | SLC5A2 (0.69) | SLC5A2SLC5A1 | |
| SCHEMBL677595 | 0.69 | SLC5A2 (0.47) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058245-B2 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20070197450-A1 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2007-08-23 | — | — | US | disclosed |
| EP-1721904-A1 | FUSED HETEROCYCLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197450-A1 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | SLC5A1, SLC5A2, GPR119 | SLC5A2 2/4885SLC5A1 1/4885CYP2C19 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.